Q-omics provides the consensus-scored E2F8 profile across patient tissues and cancer cell-line models. E2F8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, E2F8 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, E2F8 RNA expression shows 20,825 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, BLCA, and LUAD as cancer lineages where E2F8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for E2F8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes E2F8 survival associations across molecular data types. E2F8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible E2F8 RNA expression–survival associations across cancer types. High E2F8 expression shows unfavorable associations in KIRP, MESO, UVM, ACC and LIHC, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for E2F8 RNA expression.
This table summarizes E2F8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for E2F8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. E2F8 shows higher tumor expression in BLCA, KIRC, KIRP, COAD, LUAD and LIHC. The BLCA box plot shows higher E2F8 RNA expression in tumor versus normal tissue (log2 FC = +2.117, t-test p < 0.001).
This table shows molecular features associated with E2F8 in patient tissues and cancer cell lines. In patient samples, E2F8 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, E2F8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
